TY - JOUR
T1 - Cardiovascular risks of antiretroviral therapies
AU - Mondy, Kristin
AU - Tebas, Pablo
PY - 2007
Y1 - 2007
N2 - The use of highly active antiretroviral therapy (HAART) has resulted in sustained reductions in mortality from HIV infection. In recent years, HAART has also been associated with metabolic complications that may increase patients' cardiovascular disease risk. Recent studies have begun to support a more complex interaction between HAART, HIV infection itself, and other traditional social and immunologic factors that may predispose patients to premature cardiovascular disease. Substantial progress has been made in the development of newer antiretroviral therapies that have a better metabolic profile with respect to dyslipidemia, hyperglycemia, and lipodystrophy. Optimal selection of metabolically neutral antiretroviral therapies, together with aggressive management of other modifiable coronary risk factors, may improve cardiovascular disease risk in the long term.
AB - The use of highly active antiretroviral therapy (HAART) has resulted in sustained reductions in mortality from HIV infection. In recent years, HAART has also been associated with metabolic complications that may increase patients' cardiovascular disease risk. Recent studies have begun to support a more complex interaction between HAART, HIV infection itself, and other traditional social and immunologic factors that may predispose patients to premature cardiovascular disease. Substantial progress has been made in the development of newer antiretroviral therapies that have a better metabolic profile with respect to dyslipidemia, hyperglycemia, and lipodystrophy. Optimal selection of metabolically neutral antiretroviral therapies, together with aggressive management of other modifiable coronary risk factors, may improve cardiovascular disease risk in the long term.
KW - HIV therapy
KW - Metabolic complications
UR - http://www.scopus.com/inward/record.url?scp=34047164957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34047164957&partnerID=8YFLogxK
U2 - 10.1146/annurev.med.58.072905.180040
DO - 10.1146/annurev.med.58.072905.180040
M3 - Article
C2 - 17217329
AN - SCOPUS:34047164957
VL - 58
SP - 141
EP - 155
JO - Annual Review of Medicine
JF - Annual Review of Medicine
SN - 0066-4219
ER -